1.22

3.17% -0.04

After Hours: 1.21 -0.01 -0.82%

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $1.22, with a volume of 1.79M. It is down -3.17% in the last 24 hours and down -25.15% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Previous Close:

$1.26

Open:

$1.21

24h Volume:

1.79M

Relative Volume:

0.84

Market Cap:

$250.10M

Revenue:

$12.87M

Net Income/Loss:

$-114.34M

P/E Ratio:

-1.4111

EPS:

-0.8646

Net Cash Flow:

$-79.23M

1W Performance:

-36.79%

1M Performance:

-25.15%

6M Performance:

-39.30%

1Y Performance:

-54.48%

1-Day Range:

$1.19

$1.24

1-Week Range:

$1.17

$1.79

52-Week Range:

$1.17

$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1162)

Industry

Biotechnology (673)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	1.22	250.10M	12.87M	-114.34M	-79.23M	-0.8646
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

08:56 AM

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks

08:56 AM

08:01 AM

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

08:01 AM

08:00 AM

Taysha Expands Team: 822,000 Stock Options Awarded in Strategic Growth Move - Stock Titan

08:00 AM

Apr 03, 2025

At $1.32 Price, Taysha Gene Therapies Inc (TSHA) Is Sitting And Waiting - stocksregister.com

Apr 03, 2025

Mar 31, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 31, 2025

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga

Mar 31, 2025

Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com India

Mar 31, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World

Mar 31, 2025

Mar 26, 2025

Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Mar 26, 2025

Mar 19, 2025

Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey

Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025

Mar 14, 2025

Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World

Mar 14, 2025

Mar 13, 2025

Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 12, 2025

Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia

Mar 12, 2025

Mar 11, 2025

Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World

Mar 11, 2025

Mar 07, 2025

Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan

Mar 07, 2025

Mar 03, 2025

TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World

Mar 03, 2025

Mar 01, 2025

Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Mar 01, 2025

Feb 28, 2025

Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Feb 28, 2025

Feb 27, 2025

Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks

Feb 27, 2025

Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks

Feb 27, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN

Feb 27, 2025